North America Genome Editing Market Size & Outlook
Global Market
Related Markets
North America genome editing market highlights
- The North America genome editing market generated a revenue of USD 5,056.4 million in 2025.
- The market is expected to grow at a CAGR of 16.6% from 2026 to 2033.
- In terms of segment, crispr/cas9 was the largest revenue generating technology in 2025.
- CRISPR/Cas9 is the most lucrative technology segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 5,056.4 million |
| Market revenue in 2033 | USD 17,158.1 million |
| Growth rate | 16.6% (CAGR from 2026 to 2033) |
| Largest segment | Crispr/cas9 |
| Fastest growing segment | CRISPR/Cas9 |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CRISPR/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
| Key market players worldwide | Merck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc |
Other key industry trends
- In terms of revenue, North America region accounted for 44.5% of the global genome editing market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,681.5 million by 2033.
The presence of robust research infrastructure, rise in genetically modified crops, and increase in prevalence of genetic diseases are some of the major driving factors boosting the U.S. genome editing market. Moreover, in the U.S., genetic diseases such as cystic fibrosis are prevalent.
According to the Cystic Fibrosis Foundation Patient Registry, around 30,000 people are suffering from cystic fibrosis in the country. In addition, around 1,000 new cystic fibrosis cases are diagnosed every year. On the other hand, rise in the number of patent approvals for U.S.-based companies has also accelerated the adoption of genome editing tools in the country, leading to positive market growth.
For instance, in May 2020, Merck announced that two CRISPR gene editing patents were approved in the U.S. In September 2020, Editas Medicine revealed that the U.S. Patent and Trademark Office approved certain Broad’s CRISPR/Cas9 patents for priority benefits.
No credit card required*
Publish Date: Dec 09, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Genome Editing Market Scope
Genome Editing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Takara Bio Inc | View profile | 1,793 | Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, Japan, 520-0058 | www.takara-bio.co.jp |
| Caribou Biosciences Inc Ordinary Shares | View profile | 137 | 2929 7th Street, Suite 105, Berkeley, CA, United States, 94710 | www.cariboubio.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Genscript Biotech Corp Class H | View profile | 6,937 | No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, China, People's Republic of, 211100 | www.genscript.com |
| New England Biolabs | View profile | 501-1000 | Ipswich, Massachusetts, United States, North America | neb.com |
| Cellectis SA | View profile | 216 | 8, rue de la Croix Jarry, Paris, France, 75013 | www.cellectis.com |
North America Genome Editing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Genome Editing Market Outlook will help companies and investors design strategic landscapes.
Crispr/Cas9 was the largest segment with a revenue share of 50.85% in 2025.
Horizon Databook has segmented the North America genome editing market based on crispr/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2021 to 2033.
The presence of robust research infrastructure, rise in genetically modified crops, and increase in prevalence of genetic diseases are some of the major driving factors boosting the U.S. genome editing market. Moreover, in the U.S., genetic diseases such as cystic fibrosis are prevalent.
According to the Cystic Fibrosis Foundation Patient Registry, around 30,000 people are suffering from cystic fibrosis in the country. In addition, around 1,000 new cystic fibrosis cases are diagnosed every year. On the other hand, rise in the number of patent approvals for U.S.-based companies has also accelerated the adoption of genome editing tools in the country, leading to positive market growth.
For instance, in May 2020, Merck announced that two CRISPR gene editing patents were approved in the U.S. In September 2020, Editas Medicine revealed that the U.S. Patent and Trademark Office approved certain Broad’s CRISPR/Cas9 patents for priority benefits.
- North America Genome Editing Market Technology Outlook (Revenue, USD Million , 2021-2033)
- TALENs/MegaTALs
- ZFN
- Others
- (CRISPR)/Cas9
- Meganuclease
- North America Genome Editing Market Delivery Method Outlook (Revenue, USD Million , 2021-2033)
- Ex-vivo
- In-vivo
- North America Genome Editing Market Mode Outlook (Revenue, USD Million , 2021-2033)
- In-house
- Contract
- North America Genome Editing Market Application Outlook (Revenue, USD Million , 2021-2033)
- Genetic Engineering
- Clinical Applications
- North America Genome Editing Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Academic and Government Research Institutes
- Contract Research Organizations
- Biotechnology and Pharmaceutical Companies
Reasons to subscribe to Genome Editing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Genome Editing Market Outlook databook
- Our clientele includes a mix of Genome Editing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Genome Editing Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Genome Editing Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
North America Genome Editing Market, 2021-2033 (US$M)
North America genome editing market statistics, by technology, 2021-2033 (US$M)
